Xencor to receive $105M from Alexion in Ultomiris royalty settlement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Xencor to Receive $105 Million From Alexion to Resolve Ultomiris® U.S. Royalty Matter
July 29, 2026 4:01 PM EDT-- Agreement with Alexion resolves previously disclosed dispute regarding U.S. royalties --
-- Ex-U.S. royalties remain unchanged --
PASADENA, Calif.--(BUSINESS WIRE)--
Xencor, Inc. (NASDAQ: XNCR) (Xencor), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced its agreement with Alexion Pharma International Operations Limited, an Irish limited company (Alexion), to resolve a commercial dispute related to U.S. royalties on Ultomiris® (ravulizumab-cwvz) (the Settlement Agreement).
Under the Settlement Agreement, Xencor will receive $105 million in two equal... More
